Short Interest in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Increases By 7.9%

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX – Get Rating) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 666,600 shares, an increase of 7.9% from the February 13th total of 617,600 shares. Based on an average daily volume of 156,700 shares, the short-interest ratio is currently 4.3 days. Approximately 8.3% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, StockNews.com cut AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, November 16th.

Institutional Investors Weigh In On AcelRx Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Armistice Capital LLC purchased a new stake in shares of AcelRx Pharmaceuticals in the fourth quarter worth $830,000. Susquehanna International Group LLP purchased a new stake in shares of AcelRx Pharmaceuticals in the fourth quarter worth $144,000. Values First Advisors Inc. grew its stake in shares of AcelRx Pharmaceuticals by 3.5% in the third quarter. Values First Advisors Inc. now owns 794,164 shares of the specialty pharmaceutical company’s stock worth $166,000 after acquiring an additional 27,010 shares during the last quarter. Tang Capital Management LLC purchased a new stake in shares of AcelRx Pharmaceuticals in the third quarter worth $81,000. Finally, Vanguard Group Inc. grew its stake in shares of AcelRx Pharmaceuticals by 22.3% in the third quarter. Vanguard Group Inc. now owns 4,569,553 shares of the specialty pharmaceutical company’s stock worth $955,000 after acquiring an additional 831,999 shares during the last quarter.

AcelRx Pharmaceuticals Trading Down 21.0 %

NASDAQ ACRX opened at $0.87 on Wednesday. AcelRx Pharmaceuticals has a 12 month low of $0.86 and a 12 month high of $7.68. The stock has a market cap of $6.47 million, a P/E ratio of 0.14 and a beta of 0.27. The stock’s fifty day moving average price is $1.84 and its 200-day moving average price is $3.39.

About AcelRx Pharmaceuticals

(Get Rating)

AcelRx Pharmaceuticals, Inc engages in the development and commercialization of therapies use in medically supervised settings. The firm’s portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.